iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors
• To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers
• To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications

Geneva, Switzerland and Amsterdam, The Netherlands, 20 June 2024 – iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces that it has closed an EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund.

Read more…